Trillium Reports Annual 2016 Financial and Operating Results - Seite 2

(Amounts in Canadian dollars)

As of December 31, 2016, Trillium had cash of $50.5 million. For the year ended December 31, 2016, the company used $22.9 million of cash for operations; $9.6 million for the acquisition of Fluorinov Pharma Inc; and used $3.0 million for capital purchases related to its new office and laboratory facility.

Net loss for the year ended December 31, 2016 of $31.7 million was higher than the loss of $14.7 million for the year ended December 31, 2015. The net loss was higher due mainly to increased research and development program expenses of $11.7 million, higher intangible asset amortization of $3.3 million related mainly to the acquisition of Fluorinov intangible assets, and a net foreign currency loss in 2016 of $2.0 million from holding US denominated cash with a weakening US dollar, compared to a foreign currency gain in the comparable 2015 period of $6.1 million. This was partially offset by the recognition of a deferred tax recovery in relation to the acquisition of Fluorinov of $3.7 million.

Selected Consolidated Financial Information:

Consolidated statements of loss and comprehensive loss
Amounts in Canadian dollars		Year ended December 31, 2016		Year ended December 31, 2015
Research and development expenses		29,788,795		18,050,091
General and administrative expenses		3,932,910		3,184,347
Net finance costs (income)		1,691,680		(6,510,241)
Net loss and comprehensive loss for the year		31,733,085		14,733,699
Basic and diluted loss per common share		(4.06)		(2.22)
Consolidated Statements of Financial Position
Amounts in Canadian dollars		As at